U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 174 results

Status:
US Approved Rx (2008)
First approved in 2008

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Clevidipine is a dihydropyridine calcium channel blocker. Clevidipine is marketed under the trade name Cleviprex, indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is a dihydropyridine ...
Status:
US Approved Rx (2008)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Eltrombopag is a thrombopoietin (TPO) nonpeptide mimetic administered orally that activates the TPO receptor by binding to the transmembrane domain and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from ...
Status:
US Approved Rx (2008)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



DEGARELIX (FIRMAGON®) is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids. It is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release...
Status:
US Approved Rx (2023)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Icosapent is an important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardio...
Status:
US Approved Rx (2020)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Status:
US Approved Rx (2015)
First approved in 2008

Class (Stereo):
CHEMICAL (RACEMIC)



Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, ...
Status:
US Approved Rx (2017)
First approved in 2008

Class (Stereo):
CHEMICAL (RACEMIC)



Tetrabenazine (trade name Xenazine) is a monoamine depleter and used as the symptomatic treatment of chorea associated with Huntington's disease. Tetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It ...
Status:
US Approved Rx (2016)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults wit...
Status:
US Approved Rx (2017)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Dapagliflozin (trade name Farxiga in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, developed by Bristol-Myers Squibb in partnership with AstraZeneca. Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicat...
Status:
US Approved Rx (2017)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Fesoterodine (trade name Toviaz) is a prodrug of 5-hydroxymethyl tolterodine, which is also the active metabolite of tolterodine. Fesoterodine and its active metabolites are nonsubtype selective, competitive antagonists of human muscarinic receptors...